Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Gluconic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 3/20 | 0.33 |
| ▸ | PPARD | Q03181 | 3/20 | 0.33 |
| ▸ | PPARA | Q07869 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gluconic Acid SCHEMBL23069530 | 1.00 | PDE4A (0.70) | PDE4ALMNAFFAR3HDAC3HDAC1 | |
| Gluconic Acid SCHEMBL30666301 | 1.00 | PDE4A (0.70) | PDE4ALMNAFFAR3HDAC3HDAC1 | |
| Butyric Acid SCHEMBL23069534 | 0.98 | PDE4A (0.68) | PDE4ALMNAFFAR3HDAC3HDAC1 | |
| Mannitol SCHEMBL28176051 | 0.90 | FFAR3 (0.59) | PDE4ALMNAFFAR3HDAC3HDAC1 | |
| Mannitol SCHEMBL18141296 | 0.90 | FFAR3 (0.59) | PDE4ALMNAFFAR3HDAC3HDAC1 | |
| Gluconic Acid SCHEMBL4702202 | 0.88 | PDE4A (0.83) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL9193549 | 0.86 | PDE4A (0.79) | PDE4ALMNAFFAR3USP2SLCO1B1 | |
| Gluconic Acid SCHEMBL27528711 | 0.86 | PDE4A (0.61) | PDE4ALMNAUSP2TSHRCYP2C9 | |
| Gluconic Acid SCHEMBL28146406 | 0.86 | PDE4A (0.61) | PDE4ALMNAUSP2TSHRCYP2C9 | |
| Gluconic Acid SCHEMBL27486070 | 0.86 | PDE4A (0.61) | PDE4ALMNAUSP2TSHRCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207410-A1 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | NEURODERM, LTD. (IL) | 2024-06-27 | — | — | US | disclosed |
| EP-4305049-A1 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | Neuroderm Ltd (IL) | 2024-01-17 | — | — | EP | disclosed |
| US-11844754-B2 | Methods for treatment of Parkinson's disease | NEURODERM, LTD. (IL) | 2023-12-19 | — | — | US | disclosed |
| CN-116964069-A | Stabilized liquid compositions comprising levodopa-tyrosine conjugates and uses thereof | 纽罗德姆有限公司 | 2023-10-27 | — | — | CN | disclosed |
| WO-2023126945-A1 | METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | NEURODERM, LTD. (IL) | 2023-07-06 | — | — | WO | disclosed |
| US-20230157985-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | NEURODERM, LTD. (IL) | 2023-05-25 | — | — | US | disclosed |
| EP-4025200-A1 | LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF | Neuroderm Ltd (IL) | 2022-07-13 | — | — | EP | disclosed |
| WO-2021044420-A1 | LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF | NEURODERM, LTD. (IL) | 2021-03-11 | — | — | WO | disclosed |
| US-7455869-B2 | Composition for preparing artificial fruit flesh and food product containing the same | SAN-EI GEN F.F.I., INC. (JP) | 2008-11-25 | — | — | US | disclosed |
| WO-2006110119-A1 | ANTINEOPLASTIC PREPARATION | KUTNYAK VICTOR PAVLOVICH (UA) | 2006-10-19 | — | — | WO | disclosed |
| US-20040121061-A1 | Composition for preparing artificial fruit flesh and food product containing the same | SAN-EI GEN F.F.I., INC. (JP) | 2004-06-24 | — | — | US | disclosed |
| EP-1431313-A1 | Composition for preparing artificial fruit flesh and food product containing the same | San-Ei Gen F.F.I., Inc. (JP) | 2004-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11844754-B2 | Methods for treatment of Parkinson's disease | DDC, DDT, SLC6A3 | PDE4A 139/4885LMNA 3957/4885FFAR3 2930/4885 |
| US-20240207410-A1 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | COMT, TH, DDT | PDE4A 178/4885LMNA 4483/4885FFAR3 1490/4885 |
| US-20230157985-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | DDC, DDT, COMT | PDE4A 141/4885LMNA 3952/4885FFAR3 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.